CSPG4 and neoplasm: The CSPG4-specific monoclonal antibody 225.28 was shown to induce regression of tumor metastases, to inhibit spontaneous metastasis and tumor recurrence in breast cancer mouse models (15), and to inhibit the growth and recurrence of melanoma in a human melanoma xenograft model (16).